Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Among recipients with HIV, kidney transplantation from donors with HIV is noninferior to that from donors without HIV.

Unlike oral PrEP treatments, which are taken daily, the drug is administered at six-month intervals and is the longest acting injectable produced to date. In a late-stage trial, lenacapavir reduced ...

Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Kidney transplant between donors and recipients with HIV is successful, research shows, which may help addresses the organ ...

Three absurdly cheap dividend stocks that are trading at modest multiples of their expected earnings today are Merck (NYSE: ...

It is just as safe and effective for people with HIV in need of kidney transplantation to get their organ from donors who are also HIV positive as it is from donors who are not infected with the virus ...